AstraZeneca, GSK and Merck KGaA publicly disclose their patent filing and enforcement policy, and disclose or commit to disclose their patent status and licensing approach to support third party manufacture and/or supply of patented products.
AstraZeneca has a new pricing policy for its respiratory and cardiovascular disease products in certain key out-of-pocket markets in scope, based on an ability-to-pay analysis.
Nine companies have committed to R&D for antimicrobial resistance (AMR), signing the Davos Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance.
Broad consideration of socio-economic factors when setting prices for a first-line heart disease medicine in multiple priority countries*
AstraZeneca considers five socio-economic factors when setting prices for a first-line heart disease medicine and targets 27% of priority countries. This is comparatively broad as the industry considers only two socio-economic factors per strategy, on average.
AstraZeneca has developed an internal governance structure for its Healthy Heart Africa programme, consisting of a Global Advisory Board and National Steering Committee.